Literature DB >> 31977148

Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.

Christian Skorik1,2, Nathaniel K Mullin1,3, Michael Shi1,4, Yosra Zhang1,2, Phoebe Hunter1, Yang Tang1, Brianna Hilton1, Thorsten M Schlaeger1,5,6.   

Abstract

Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages.
© 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Isolating peripheral blood mononuclear cells using CPT tubes Support Protocol 1: Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1 Basic Protocol 2: PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum Basic Protocol 3: Reprogramming of expanded PBMCs with Sendai viral reprogramming particles Alternate Protocol: Reprogramming of expanded PBMCs with episomal plasmids Basic Protocol 4: Picking, expanding, and cryopreserving hiPSC clones Support Protocol 2: Testing Sendai virus kit-reprogrammed hiPSC for absence of Sendai viral RNA Support Protocol 3: Testing Epi5 kit-reprogrammed hiPSC for absence of episomal plasmid DNA Support Protocol 4: Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging Support Protocol 5: Coating plates with extracellular matrices to support hiPSC attachment and expansion. © 2020 John Wiley & Sons, Inc.

Entities:  

Keywords:  Sendai viral reprogramming; episomal reprogramming; human induced pluripotent stem cells (hiPSCs); reprogramming

Mesh:

Substances:

Year:  2020        PMID: 31977148      PMCID: PMC7176073          DOI: 10.1002/cpsc.103

Source DB:  PubMed          Journal:  Curr Protoc Stem Cell Biol        ISSN: 1938-8969


  38 in total

Review 1.  New ISSCR guidelines underscore major principles for responsible translational stem cell research.

Authors:  Insoo Hyun; Olle Lindvall; Lars Ahrlund-Richter; Elena Cattaneo; Marina Cavazzana-Calvo; Giulio Cossu; Michele De Luca; Ira J Fox; Claude Gerstle; Robert A Goldstein; Göran Hermerén; Katherine A High; Hyun Ok Kim; Hin Peng Lee; Ephrat Levy-Lahad; Lingsong Li; Bernard Lo; Daniel R Marshak; Angela McNab; Megan Munsie; Hiromitsu Nakauchi; Mahendra Rao; Heather M Rooke; Carlos Simon Valles; Alok Srivastava; Jeremy Sugarman; Patrick L Taylor; Anna Veiga; Adrianne L Wong; Laurie Zoloth; George Q Daley
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

2.  Basement membrane complexes with biological activity.

Authors:  H K Kleinman; M L McGarvey; J R Hassell; V L Star; F B Cannon; G W Laurie; G R Martin
Journal:  Biochemistry       Date:  1986-01-28       Impact factor: 3.162

3.  Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines.

Authors:  Christoph Bock; Evangelos Kiskinis; Griet Verstappen; Hongcang Gu; Gabriella Boulting; Zachary D Smith; Michael Ziller; Gist F Croft; Mackenzie W Amoroso; Derek H Oakley; Andreas Gnirke; Kevin Eggan; Alexander Meissner
Journal:  Cell       Date:  2011-02-04       Impact factor: 41.582

4.  Derivation of human embryonic stem cells in defined conditions.

Authors:  Tenneille E Ludwig; Mark E Levenstein; Jeffrey M Jones; W Travis Berggren; Erika R Mitchen; Jennifer L Frane; Leann J Crandall; Christine A Daigh; Kevin R Conard; Marian S Piekarczyk; Rachel A Llanas; James A Thomson
Journal:  Nat Biotechnol       Date:  2006-01-01       Impact factor: 54.908

Review 5.  Nonintegrating Human Somatic Cell Reprogramming Methods.

Authors:  Thorsten M Schlaeger
Journal:  Adv Biochem Eng Biotechnol       Date:  2018       Impact factor: 2.635

6.  Generation of Human Induced Pluripotent Stem Cells Using a Defined, Feeder-Free Reprogramming System.

Authors:  Seonmi Park; Gustavo Mostoslavsky
Journal:  Curr Protoc Stem Cell Biol       Date:  2018-05-04

7.  An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells.

Authors:  Keisuke Okita; Tatsuya Yamakawa; Yasuko Matsumura; Yoshiko Sato; Naoki Amano; Akira Watanabe; Naoki Goshima; Shinya Yamanaka
Journal:  Stem Cells       Date:  2013-03       Impact factor: 6.277

8.  Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.

Authors:  Florian T Merkle; Sulagna Ghosh; Nolan Kamitaki; Jana Mitchell; Yishai Avior; Curtis Mello; Seva Kashin; Shila Mekhoubad; Dusko Ilic; Maura Charlton; Genevieve Saphier; Robert E Handsaker; Giulio Genovese; Shiran Bar; Nissim Benvenisty; Steven A McCarroll; Kevin Eggan
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

9.  A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs.

Authors:  Bahram Valamehr; Ramzey Abujarour; Megan Robinson; Thuy Le; David Robbins; Daniel Shoemaker; Peter Flynn
Journal:  Sci Rep       Date:  2012-01-06       Impact factor: 4.379

Review 10.  Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.

Authors:  Erika Kleiderman; Audrey Boily; Craig Hasilo; Bartha Maria Knoppers
Journal:  Stem Cell Res Ther       Date:  2018-11-08       Impact factor: 6.832

View more
  1 in total

Review 1.  Induced Pluripotent Stem Cells as a Tool for Modeling Hematologic Disorders and as a Potential Source for Cell-Based Therapies.

Authors:  Ponthip Pratumkaew; Surapol Issaragrisil; Sudjit Luanpitpong
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.